Next Article in Journal
Activation of the Sphingosine 1 Phosphate–Rho Pathway in Pterygium and in Ultraviolet-Irradiated Normal Conjunctiva
Next Article in Special Issue
Solid Nanocrystals of Rebamipide Promote Recovery from Indomethacin-Induced Gastrointestinal Bleeding
Previous Article in Journal
Diagnostic Performance and Prognostic Value of PET/CT with Different Tracers for Brain Tumors: A Systematic Review of Published Meta-Analyses
Previous Article in Special Issue
Recent Trends in Decellularized Extracellular Matrix Bioinks for 3D Printing: An Updated Review
Open AccessArticle

Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy

1
Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju 61469, Korea
2
Department of Surgery, School of Medicine, Konkuk University, Seoul 05030, Korea
3
Department of Dental Hygiene, College of Health Sciences, Cheongju University, Cheongju 28503, Korea
4
Department of Obstetrics & Gynecology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
5
Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
6
Institute of Cell and Tissue Engineering, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this study.
Int. J. Mol. Sci. 2019, 20(19), 4671; https://doi.org/10.3390/ijms20194671
Received: 5 August 2019 / Revised: 10 September 2019 / Accepted: 19 September 2019 / Published: 20 September 2019
(This article belongs to the Special Issue Cell-Biomaterial Interaction 2019)
We used a hydrogel-mediated dual drug delivery approach, based on an injectable glycol chitosan (GC) hydrogel, doxorubicin hydrochloride (DOX⋅HCl), and a complex of beta-cyclodextrin (β-CD) and paclitaxel (PTX) (GDCP) for breast cancer therapy in vitro and in vivo. The hydrogel was swollen over 3 days and remained so thereafter. After an initial burst period of 7 hours, the two drugs were released in a sustained manner for 7 days. The in vitro cell viability test showed that GDCP had a better anticancer effect than well plate and DOX⋅HCl/PTX (DP). In addition, the in vivo tests, which evaluated the anticancer effect, systemic toxicity, and histology, proved the feasibility of GDCP as a clinical therapy for breast cancer. View Full-Text
Keywords: injectable glycol chitosan; doxorubicin hydrochloride; beta-cyclodextrin; paclitaxel; breast cancer therapy injectable glycol chitosan; doxorubicin hydrochloride; beta-cyclodextrin; paclitaxel; breast cancer therapy
Show Figures

Figure 1

MDPI and ACS Style

Hyun, H.; Yoo, Y.B.; Kim, S.Y.; Ko, H.S.; Chun, H.J.; Yang, D.H. Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy. Int. J. Mol. Sci. 2019, 20, 4671.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop